NASDAQ · TGTX
TG Therapeutics, Inc.
U.S. listed stock · USD15-minute delay
Find an instrument
- AppleAAPL · NASDAQResearch →
- MicrosoftMSFT · NASDAQResearch →
- NvidiaNVDA · NASDAQResearch →
- AmazonAMZN · NASDAQResearch →
- AlphabetGOOGL · NASDAQResearch →
- Meta PlatformsMETA · NASDAQResearch →
- TeslaTSLA · NASDAQResearch →
- JPMorgan ChaseJPM · NYSEResearch →
- ExxonMobilXOM · NYSEResearch →
- WalmartWMT · NASDAQResearch →
- S&P 500 IndexSPX · S&PResearch →
- Nasdaq 100 IndexNDX · NASDAQResearch →
- Dow Jones Industrial AverageDJI · Dow JonesResearch →
- Cboe Volatility IndexVIX · CboeResearch →
- U.S. Dollar IndexDXY · ICEResearch →
- VIX futuresVX1! · Cboe Futures ExchangeResearch →
- DAX futuresFDAX1! · EurexResearch →
- Euro Stoxx 50 futuresFESX1! · EurexResearch →
- E-mini S&P 500 futuresES1! · CMEResearch →
- E-mini Nasdaq 100 futuresNQ1! · CMEResearch →
- E-mini Dow futuresYM1! · CBOTResearch →
- E-mini Russell 2000 futuresRTY1! · CMEResearch →
- WTI crude oil futuresCL1! · NYMEXResearch →
- Natural gas futuresNG1! · NYMEXResearch →
- Gold futuresGC1! · COMEXResearch →
- Silver futuresSI1! · COMEXResearch →
- Euro FX futures6E1! · CMEResearch →
- Japanese yen futures6J1! · CMEResearch →
- BitcoinBTCUSD · BitstampResearch →
- EtherETHUSD · BitstampResearch →
- Research Any U.S. stock or ETF tickerResearch →
No matching names. Type a U.S. stock ticker (for example MU) to research it.
Loading price chart…
15-minute delay. Chart times and available timeframes are controlled by the provider.
Earnings
Earnings calendarEarnings announcement for TGTX: Nov 2, 2026
TG Therapeutics, Inc. Common Stock is estimated to report earnings on 11/02/2026. The upcoming earnings date is derived from an algorithm based on a company's historical reporting dates. Our vendor, Zacks Investment Research, might revise this date in the future, once the company announces the actual earnings date. According to Zacks Investment Research, based on 4 analysts' forecasts, the consensus EPS forecast for the quarter is $0.37. The reported EPS for the same quarter last year was $2.43.
| Fiscal quarter end | Consensus EPS forecast | High | Low | Estimates |
|---|---|---|---|---|
| Sep 2026 | $0.37 | $0.63 | $0.22 | 4 |
| Dec 2026 | $0.38 | $0.45 | $0.25 | 4 |
| Mar 2027 | $0.54 | $0.54 | $0.54 | 1 |
| Jun 2027 | $0.71 | $0.71 | $0.71 | 1 |
Source: Nasdaq, based on Zacks Investment Research consensus estimates. Dates marked as expected may change.
News
Zacks · BNK Invest- Zacks · Oct 29, 2:11 PM EDTINCY Q3 Loss Narrower Than Expected, Sales Beat, FY'26 View RaisedIncyte's Q3 2026 revenues beat estimates as strong product demand lifts sales 14%, prompting higher 2026 guidance despite acquisition-driven losses.
- Zacks · Oct 29, 11:52 AM EDTVKTX Q3 Earnings Miss Estimates Amid Rising Clinical ExpensesViking Therapeutics' Q3 loss widens as rising costs weigh on results, while its obesity drug candidate advances through phase III studies.
- Zacks · Oct 29, 11:31 AM EDTAmarin's Q3 Earnings Beat Estimates, Revenues Miss MarkAMRN's Q3 2026 earnings surpass estimates despite declining revenues. Global Vascepa/Vazkepa demand grows 55% and cash reserves increase.
- Zacks · Oct 29, 11:06 AM EDTGRAIL Q3 Earnings Ahead: Galleri Test Adoption to Drive GrowthGRAL's Q3 earnings should have benefited from rising Galleri test adoption, expanding digital health partnerships and growing clinical evidence of cancer detection.
- BNK Invest · Oct 29, 10:52 AM EDTNoteworthy ETF Outflows: IJT, PTGX, VSAT, TGTXLooking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the iShares S&P Small-Cap 600 Growth ETF (Symbol: IJT) where we have detected an approximate $180.4 million dollar outflow — that's a 2.4% decrease
- Zacks · Oct 29, 9:43 AM EDTBHC Q3 Earnings Beat on Salix Growth, Stock Gains 9% as Outlook RisesBausch Health shares jump 9% as Q3 earnings top estimates, driven by Xifaxan-led Salix growth, improved profitability and raised 2026 guidance.
- Zacks · Oct 29, 9:22 AM EDTRecursion Pharmaceuticals to Report Q3 Earnings: What's in the Cards?RXRX heads into Q3 earnings with key collaboration milestones, advancing clinical programs and upcoming pipeline updates that could shape its outlook.
- Zacks · Oct 28, 12:11 PM EDTBIIB's Q3 Earnings Beat, New Drugs Aid Sales, '26 EPS View TightenedBiogen's Q3 earnings and revenues beat estimates as growth drugs drive sales, while the company tightens its 2026 adjusted EPS outlook amid rising costs.
- Zacks · Oct 28, 10:50 AM EDTLiquidia Gears Up to Report Q3 Earnings: What Can Investors Expect?LQDA's Q3 results will spotlight the impact of its legal settlement with UTHR, cash flow pressures, profitability prospects and pipeline progress.
- Zacks · Oct 28, 10:45 AM EDTGSK Q3 Earnings Top Mark, Stock Down on Soft Vaccines SalesGSK's Q3 earnings beat estimates as HIV, oncology and respiratory medicines drive revenue growth, while declining vaccine sales weigh on shares.
- Zacks · Oct 28, 9:27 AM EDTEnvista Q3 Earnings Ahead: Product Innovation to Drive GrowthNVST's Q3 earnings may have gained from Spark aligner growth, new product launches and improving margins. Can innovation drive another earnings beat?
- Zacks · Oct 27, 11:16 AM EDTHCA Healthcare Q3 Earnings Beat Estimates on Higher AdmissionsHCA's Q3 earnings and revenues beat estimates on higher admissions and ER visits, while rising costs and fewer surgeries temper growth.
Stories from Nasdaq.com, including Zacks, The Motley Fool and Barchart. They open on the publisher’s site; AiFs Market does not edit or endorse them.
Company profile
Loading company profile…
Financials
Loading fundamental data…
More headlines
More stories for TG Therapeutics, Inc. from TradingView. Coverage varies.
Loading related news…
Quotes, charts, company information and headlines are supplied by TradingView. Data may be delayed or unavailable. This page is for market research and does not provide investment advice.